Christopher MBA - MannKind Corp Chief Officer
| MNKD Stock | USD 6.78 0.17 2.57% |
Executive
Christopher MBA is Chief Officer of MannKind Corp
| Age | 49 |
| Address | 1 Casper Street, Danbury, CT, United States, 06810 |
| Phone | 818 661 5000 |
| Web | https://www.mannkindcorp.com |
MannKind Corp Management Efficiency
The company has return on total asset (ROA) of 0.0912 % which means that it generated a profit of $0.0912 on every $100 spent on assets. This is way below average. MannKind Corp's management efficiency ratios could be used to measure how well MannKind Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.03. In addition to that, Return On Capital Employed is expected to decline to 0.02. At present, MannKind Corp's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 392.1 M, whereas Non Current Assets Total are forecasted to decline to about 87.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Nate Sanburn | Verastem | N/A | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| MD BA | Adaptimmune Therapeutics Plc | 60 | |
| Brenda Everson | Bio Techne Corp | N/A | |
| Martin Wirtz | Bio Techne Corp | N/A | |
| Colleen Mockbee | Verastem | N/A | |
| Kevin Eggan | Biomarin Pharmaceutical | N/A | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Greg Guyer | Biomarin Pharmaceutical | 62 | |
| John Lunger | Adaptimmune Therapeutics Plc | 54 | |
| Indira Naidu | Immutep Ltd ADR | N/A | |
| RPh PharmD | Affimed NV | 40 | |
| MD MSc | Verastem | 67 | |
| Amy Pooler | Sangamo Therapeutics | N/A | |
| Holly Hobson | United Therapeutics | N/A | |
| Biren Shah | Elevation Oncology | N/A | |
| Deborah Wong | Legend Biotech Corp | N/A | |
| Janet Graesser | Vaxcyte | N/A | |
| Humaira Serajuddin | Biomarin Pharmaceutical | N/A | |
| Kevin Smyth | Bio Techne Corp | N/A | |
| Russell Schundler | Liquidia Technologies | 49 | |
Management Performance
| Return On Asset | 0.0912 |
MannKind Corp Leadership Team
Elected by the shareholders, the MannKind Corp's board of directors comprises two types of representatives: MannKind Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MannKind. The board's role is to monitor MannKind Corp's management team and ensure that shareholders' interests are well served. MannKind Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MannKind Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Bedard, Senior Affairs | ||
| Burkhard MD, Executive Officer | ||
| Stuart Tross, Chief People Officer | ||
| Christopher MBA, Chief Officer | ||
| Lauren Sabella, Executive COO | ||
| Michael PharmD, CEO Director | ||
| McCauley JD, Chief Officer | ||
| David Thomson, Corporate Vice President General Counsel, Corporate Secretary | ||
| Rosabel Alinaya, Acting CFO, Senior Vice President Chief Accounting Officer | ||
| MS MBA, Chief Officer | ||
| Rosabel CPA, VP Treasury | ||
| Matthew PharmD, Senior Unit | ||
| Sanjay MBA, Executive Operations | ||
| Steven Binder, CFO, Principal Accounting Officer | ||
| Thomas MD, Chief Officer | ||
| Dr JD, General VP |
MannKind Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MannKind Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0912 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 1.86 B | ||||
| Shares Outstanding | 275.78 M | ||||
| Shares Owned By Insiders | 1.83 % | ||||
| Shares Owned By Institutions | 56.60 % | ||||
| Number Of Shares Shorted | 42.04 M | ||||
| Price To Earning | 2.27 X | ||||
| Price To Sales | 7.00 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether MannKind Corp is a strong investment it is important to analyze MannKind Corp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MannKind Corp's future performance. For an informed investment choice regarding MannKind Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MannKind Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For information on how to trade MannKind Stock refer to our How to Trade MannKind Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MannKind Corp. If investors know MannKind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MannKind Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.246 | Earnings Share 0.08 | Revenue Per Share 0.982 | Quarterly Revenue Growth 0.367 | Return On Assets 0.0912 |
The market value of MannKind Corp is measured differently than its book value, which is the value of MannKind that is recorded on the company's balance sheet. Investors also form their own opinion of MannKind Corp's value that differs from its market value or its book value, called intrinsic value, which is MannKind Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MannKind Corp's market value can be influenced by many factors that don't directly affect MannKind Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MannKind Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if MannKind Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MannKind Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.